Mariner
NTLA icon

Mariner’s Intellia Therapeutics NTLA Stock Holding History

Mariner’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$665K Buy
+51,903
New +$661K ﹤0.01% 2271
2025
Q3 		– Sell
-14,507
Closed -$136K – 3699
2025
Q2 		$136K Sell
14,507
-2,046
-12% -$16.8K ﹤0.01% 3175
2025
Q1 		$118K Buy
16,553
+1,733
+12% +$17.5K ﹤0.01% 3150
2024
Q4 		$173K Sell
14,820
-2,496
-14% -$39K ﹤0.01% 3056
2024
Q3 		$357K Buy
17,316
+1,822
+12% +$42K ﹤0.01% 2422
2024
Q2 		$347K Sell
15,494
-1,779
-10% -$42.4K ﹤0.01% 2340
2024
Q1 		$475K Buy
17,273
+466
+3% +$12.9K ﹤0.01% 2064
2023
Q4 		$512K Buy
16,807
+2,610
+18% +$75K ﹤0.01% 1917
2023
Q3 		$449K Buy
14,197
+160
+1% +$6.21K ﹤0.01% 1853
2023
Q2 		$572K Buy
14,037
+165
+1% +$6.69K ﹤0.01% 1650
2023
Q1 		$516K Buy
13,872
+697
+5% +$27.3K ﹤0.01% 1670
2022
Q4 		$460K Sell
13,175
-364
-3% -$17.3K ﹤0.01% 1702
2022
Q3 		$758K Sell
13,539
-3,721
-22% -$231K ﹤0.01% 1194
2022
Q2 		$894K Buy
17,260
+1,034
+6% +$52.5K ﹤0.01% 938
2022
Q1 		$1.18M Buy
16,226
+1,195
+8% +$101K ﹤0.01% 883
2021
Q4 		$1.78M Buy
15,031
+84
+0.6% +$10.5K 0.01% 684
2021
Q3 		$2M Sell
14,947
-38
-0.3% -$5.75K 0.01% 538
2021
Q2 		$2.43M Buy
+14,985
New +$1.17M 0.02% 453

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Mariner's NTLA Position: Q1 2026 in Review

Mariner opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 51,903 shares worth $665K. The stake represents ﹤0.01% of the portfolio and ranks #2271 among its holdings. This is a return to the name: Mariner previously reported a position in NTLA as recently as Q2 2025.

Mariner first reported a position in NTLA in Q2 2021 and has held it in 18 quarters since. The position peaked at $2.43M in Q2 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Mariner held 51,903 shares of Intellia Therapeutics worth $665K as of Q1 2026.
  • Intellia Therapeutics was a new Mariner position in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2271 holding.
  • Mariner first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 18 quarters since.
  • Mariner's Intellia Therapeutics position peaked at $2.43M in Q2 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.